Literature DB >> 17805549

Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Cem Terzi1, Aras Emre Canda, Ozgul Sagol, Koray Atila, Devrim Sonmez, Mehmet Fuzun, Ilknur B Gorken, Ilhan Oztop, Funda Obuz.   

Abstract

PURPOSE: The ability to predict response to chemoradiotherapy before the treatment may allow protecting poorly responding patients from the side effects of neoadjuvant treatment. Several molecular markers have been proposed to radio and chemosensitivity of rectal cancer. In this study, from pre-irradiation tumor biopsies, a novel and promising candidate factor survivin, and p53 and Ki-67 were assessed as predictors of response to preoperative chemoradiotherapy.
MATERIALS AND METHODS: Expression of each marker was evaluated by immunohistochemistry on pretreatment biopsies from 37 patients having rectal cancer treated with preoperative chemoradiotherapy and curative surgery. Treatment response was assessed histopathologically in the resected surgical specimen.
RESULTS: There was no correlation between expression of p53, Ki-67, and survivin with response to preoperative chemoradiotherapy and prognosis.
CONCLUSIONS: Our data suggest that these molecular markers are not helpful to identify patients who would have benefit from neoadjuvant treatment of rectal cancer. Further investigations are necessary to select patients for preoperative treatment based on analysis of the preoperative biopsies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805549     DOI: 10.1007/s00384-007-0376-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  61 in total

1.  [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer].

Authors:  U Tiefenbacher; F Wenz
Journal:  Strahlenther Onkol       Date:  2001-12       Impact factor: 3.621

Review 2.  Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.

Authors:  F M Smith; J V Reynolds; N Miller; R B Stephens; M J Kennedy
Journal:  Eur J Surg Oncol       Date:  2005-12-01       Impact factor: 4.424

Review 3.  Radiosensitivity of tumor cells. Oncogenes and apoptosis.

Authors:  L T Peltenburg
Journal:  Q J Nucl Med       Date:  2000-12

4.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.

Authors:  Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.

Authors:  C B Begg; P P Carbone
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

6.  Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients.

Authors:  C G Fu; O Tominaga; H Nagawa; M E Nita; T Masaki; G Ishimaru; Y Higuchi; T Tsuruo; T Muto
Journal:  Dis Colon Rectum       Date:  1998-01       Impact factor: 4.585

7.  Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy.

Authors:  R D Marsh; N M Chu; J N Vauthey; W M Mendenhall; G Y Lauwers; C Bewsher; E M Copeland
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

8.  Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Thomas Papadopoulos; Marc Bigalke; Klaus Günther; Christoph Schick; Andrea Peters; Rolf Sauer; Franz Rödel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

9.  Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas.

Authors:  M Z Gilcrease; L Truong; R W Brown
Journal:  Hum Pathol       Date:  1996-12       Impact factor: 3.466

10.  Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor.

Authors:  Claus Rödel; Joachim Haas; Anke Groth; Gerhard G Grabenbauer; Rolf Sauer; Franz Rödel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

View more
  14 in total

1.  High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Kyubo Kim; Eui Kyu Chie; Hong-Gyun Wu; Sang Gyun Kim; Seung-Hee Lee; Gyeong Hoon Kang; Chang Lim Hyun; Sung W Ha
Journal:  Int J Colorectal Dis       Date:  2011-03-19       Impact factor: 2.571

2.  Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients.

Authors:  Aras Emre Canda; Cem Terzi; Ilknur B Gorken; Ilhan Oztop; Selman Sokmen; Mehmet Fuzun
Journal:  Int J Colorectal Dis       Date:  2009-09-26       Impact factor: 2.571

3.  Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer.

Authors:  Dermot T McDowell; Fraser M Smith; John V Reynolds; Stephen G Maher; Collette Adida; Paul Crotty; Eoin F Gaffney; Donal Hollywood; Brian Mehigan; Richard B Stephens; M J Kennedy
Journal:  Int J Colorectal Dis       Date:  2009-07-11       Impact factor: 2.571

4.  Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy.

Authors:  Taek-Keun Nam; Ji-Shin Lee; Hyeong-Rok Kim; Sung-Ja Ahn; Ju-Young Song; Mee Sun Yoon
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

5.  Influence of neoadjuvant chemoradiotherapy on the anal sphincter: ultrastructural damage may be critical.

Authors:  Xiaoming Zhu; Zheng Lou; Haifeng Gong; Ronggui Meng; Liqiang Hao; Wei Zhang
Journal:  Int J Colorectal Dis       Date:  2016-06-08       Impact factor: 2.571

Review 6.  Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.

Authors:  Koh Miura; Wataru Fujibuchi; Kazuyuki Ishida; Takeshi Naitoh; Hitoshi Ogawa; Toshinori Ando; Nobuki Yazaki; Kazuhiro Watanabe; Sho Haneda; Chikashi Shibata; Iwao Sasaki
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

7.  Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

Authors:  Hee Jeong Cho; Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Soo Jung Lee; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

8.  Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.

Authors:  Elisa Melucci; Maurizio Cosimelli; Livio Carpanese; Giuseppe Pizzi; Francesco Izzo; Francesco Fiore; Rita Golfieri; Emanuela Giampalma; Isabella Sperduti; Cristiana Ercolani; Rosa Sciuto; Raffaello Mancini; Carlo Garufi; Maria Grazia Diodoro; Marcella Mottolese
Journal:  J Exp Clin Cancer Res       Date:  2013-03-06

9.  Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy.

Authors:  Abhishek A Solanki; Daniel T Chang; Stanley L Liauw
Journal:  Onco Targets Ther       Date:  2013-08-14       Impact factor: 4.147

10.  P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Authors:  Min-Bin Chen; Xiao-Yang Wu; Rong Yu; Chen Li; Li-Qiang Wang; Wei Shen; Pei-Hua Lu
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.